Inclusion Criteria:

• * Eight years or older with HNC diagnosis confirmed histologically
• o Stage 1-3 HNC pathologically confirmed diagnosis of squamous cell carcinoma of the oropharynx, larynx, hypopharynx, nasopharyngeal, or oral cavity
• * Plan to receive radiotherapy (\>60 Gy), chemo-irradiation or bio-radiation either as primary or as a post-operative treatment to the head and neck region
• * Eastern Cooperative Oncology Group Performance Status (ECOGPS) performance status 0 or 1
• * Comply with the study protocol
• * Capable of signing a written informed consent

Exclusion Criteria:

• * An allergy, intolerance, or contraindication to colchicine
• * Current treatment with colchicine for medical conditions, e.g. gout and Familial Mediterranean Fever (FMF)
• * Estimated glomerular filtration rate (GFR) \< 55 ml/min since colchicine should not be given
• * Severe liver disease or current aminotransferase levels of more than 1.5 times the upper limit of the normal range
• * Previous irradiation to the head and/or neck region
• * Distant metastatic disease or locally recurrent disease
• * Pre-existing skin rashes, ulcerations, or open wounds in the treatment area
• * Known allergic and other systemic skin diseases even when not directly affecting irradiated fields
• * Substance abuse, medical conditions, and/or social issues that would limit conduct or follow-up in the research study, in the opinion of the investigator
• * Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator
• * Using high doses of non-steroidal anti-inflammatory drugs
• * Pregnant and lactating women
• * Psychiatric illness that would prevent the patient from giving informed consent
• * Taking cetuximab or other radiosensitizing agents.